Abstract
Background: Dolutegravir (DTG)-based antiretroviral treatment is now the recommended regimen because of its high efficacy and fewer adverse effects. Nonetheless, hyperglycemia as adverse effect of DTG was reported in few clinical observations. Methods: A case-control study was carried out among DTG-based antiretroviral therapy (ART) users during the study period. EPI Info version 4.8 and SPSS version 26 were used for data entry and analysis, respectively. Binary logistic regression model was used to determine association between risk factors and outcome measures. The associated factors of hyperglycemia were identified using the odds ratio. A P-value
Author supplied keywords
Cite
CITATION STYLE
Liknaw, A., Tadesse, A., Hailu, W., Tesfaye, T., & Tadesse, M. (2025). Determinants of Hyperglycemia in Adult People Living With HIV Taking Dolutegravir- Based Antiretroviral Therapy at University of Gondar Hospital, North West Ethiopia, 2022: A Case-Control Study. Journal of the International Association of Providers of AIDS Care, 24. https://doi.org/10.1177/23259582251375873
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.